Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1400580 | 0.98 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL12798611 | 0.90 | PPARD (0.85) | PPARDPPARA | |
| SCHEMBL12798519 | 0.89 | PPARD (0.95) | PPARDPPARA | |
| SCHEMBL3025900 | 0.86 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL10216248 | 0.83 | PPARD (0.75) | PPARDPPARA | |
| SCHEMBL15627370 | 0.83 | PPARD (0.75) | PPARDPPARA | |
| SCHEMBL10216246 | 0.83 | PPARD (0.75) | PPARDPPARA | |
| SCHEMBL1400258 | 0.83 | PPARD (0.74) | PPARDPPARA | |
| SCHEMBL1400175 | 0.80 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL1400781 | 0.79 | PPARD (0.76) | PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714004-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-05-11 | — | — | US | claimed |
| US-20060084680-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-04-20 | — | — | US | claimed |
| EP-1578715-A2 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | Bayer Pharmaceuticals Corporation (US) | 2005-09-28 | — | — | EP | claimed |
| WO-2004058174-A2 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-07-15 | — | — | WO | claimed |
| US-7906653-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER HEALTHCARE LLC (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100204472-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | CANTIN LOUIS-DAVID | 2010-08-12 | — | — | US | disclosed |
| US-7714004-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-20060084680-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084680-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | INSR, ACACA, IAPP | PPARD 978/4885PPARA 365/4885 |
| US-20100204472-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | INSR, ACACA, IAPP | PPARD 978/4885PPARA 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.